Can we see the wood from the trees in ES-SCLC?

Much of the noise and attention in lung cancer is usually focused on non-small cell lung cancer (NSCLC) at cancer conferences.

While it has a greater prevalence than its more difficult to treat cousin, small-cell lung cancer (SCLC), the good news is there are now quite a few emerging novel agents and targets being evaluated in this disease.

Here we highlight and discuss some of the progress being made (or not) in the context of the broader landscape…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by